U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940427) titled 'Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis' on April 14.
Brief Summary: The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose and track fibrotic lung disease activity.
Participants will undergo up to 4 PET/MRI scans using the FAPI radiotracer.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Fibrosis Lung
Intervention:
DRUG: FAPI tracer
radioactive substance called a "tracer" injected into the arm
...